A case of advanced lung adenocarcinoma with cavity formation shrunken by bevacizumab added on the 3rd course of 6th-line chemotherapy

Masaki Miyazaki, Katsuhiko Naoki, Takashi Sato, Kyuto Tanaka, Keishi Tsuzuki, Shuichi Yoshida, Katsuyoshi Tomomatsu, Sadatomo Tasaka, Kenzo Soejima, Koichi Sayama, Koichiro Asano

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A 65-year-old man was pointed out to have an abnormal lung shadow by chest radiograph in a medical examination in 2007. An extensive examination diagnosed him as a case of advanced lung adenocarcinoma. He was treated by chemotherapy up to the 5th-line (cisplatin+docetaxel-→CPT-11+S-1-→amrubicin- →gemcitabine+vinorelbine-→pemetrexed), and the evaluation after the 5th-line treatment revealed disease progression. As he still maintained good performance status, the 6th-line treatment with carboplatin (AUC6, day 1 ) + paclitaxel (200 mg/m2, day 1) (Q3W) was administered in March, 2010. The tumor size had been increasing slightly after 2 courses of chemotherapy, although it was within the range of stable disease. Therefore, bevacizumab (15 mg/kg, day 1) was added after the 3rd course of treatment, and the tumor began shrinking obviously with cavity formation. Although the positioning of bevacizumab has not been established after 2nd-line treatment for advanced non-small cell lung carcinoma, we experienced a case of good tumor response by adding the bevacizumab in the middle of the 6th-line chemotherapy.

Original languageEnglish
Pages (from-to)421-424
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Volume39
Issue number3
Publication statusPublished - 2012 Mar

Keywords

  • Advanced non-small cell lung carcinoma
  • Bevacizumab
  • Chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A case of advanced lung adenocarcinoma with cavity formation shrunken by bevacizumab added on the 3rd course of 6th-line chemotherapy'. Together they form a unique fingerprint.

  • Cite this

    Miyazaki, M., Naoki, K., Sato, T., Tanaka, K., Tsuzuki, K., Yoshida, S., Tomomatsu, K., Tasaka, S., Soejima, K., Sayama, K., & Asano, K. (2012). A case of advanced lung adenocarcinoma with cavity formation shrunken by bevacizumab added on the 3rd course of 6th-line chemotherapy. Japanese Journal of Cancer and Chemotherapy, 39(3), 421-424.